Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NANP | Q8TBE9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16282666 | 1.00 | L3MBTL1 (0.46) | L3MBTL1NANP | |
| SCHEMBL16284126 | 1.00 | L3MBTL1 (0.46) | L3MBTL1NANP | |
| SCHEMBL22748729 | 1.00 | L3MBTL1 (0.46) | L3MBTL1NANP | |
| SCHEMBL22748730 | 1.00 | L3MBTL1 (0.46) | L3MBTL1NANP | |
| SCHEMBL22748645 | 1.00 | L3MBTL1 (0.46) | L3MBTL1NANP | |
| SCHEMBL22748702 | 1.00 | L3MBTL1 (0.46) | L3MBTL1NANP | |
| SCHEMBL22748642 | 1.00 | L3MBTL1 (0.46) | L3MBTL1NANP | |
| SCHEMBL22748791 | 1.00 | L3MBTL1 (0.46) | L3MBTL1NANP | |
| SCHEMBL22748705 | 1.00 | L3MBTL1 (0.46) | L3MBTL1NANP | |
| SCHEMBL29462897 | 1.00 | L3MBTL1 (0.46) | L3MBTL1NANP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197905-A1 | LEGIONAMINIC ACID GLYCOSYLTRANSFERASES FOR CHEMOENZYMATIC SYNTHESIS OF GLYCANS AND GLYCOCONJUGATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-06-19 | — | — | US | claimed |
| WO-2025049634-A1 | GLYCAN CONJUGATE COMPOSITIONS AND METHODS | GANNA BIO, INC. (US) | 2025-03-06 | — | — | WO | claimed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | claimed |
| WO-2023183781-A2 | LEGIONAMINIC ACID GLYCOSYLTRANSFERASES FOR CHEMOENZYMATIC SYNTHESIS OF GLYCANS AND GLYCOCONJUGATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-09-28 | — | — | WO | claimed |
| EP-4605009-A2 | GLYCAN CONJUGATE COMPOSITIONS AND METHODS | GanNA Bio, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-4594530-A1 | NUCLEIC ACID SEQUENCING COMPONENTS INCLUDING A GLYCOLIPID BI-LAYER | Illumina, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250242035-A1 | GLYCAN CONJUGATE COMPOSITIONS AND METHODS | GANNA BIO, INC. | 2025-07-31 | — | — | US | disclosed |
| US-20250197905-A1 | LEGIONAMINIC ACID GLYCOSYLTRANSFERASES FOR CHEMOENZYMATIC SYNTHESIS OF GLYCANS AND GLYCOCONJUGATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-06-19 | — | — | US | disclosed |
| WO-2025049634-A1 | GLYCAN CONJUGATE COMPOSITIONS AND METHODS | GANNA BIO, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| US-20240190912-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE CONTAINING MOLECULES USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-13 | — | — | US | disclosed |
| US-20240190913-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE CONTAINING MOLECULES USING THE SAME | DONALDSON COMPANY, INC. | 2024-06-13 | — | — | US | disclosed |
| US-20240189797-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE BINDING DOMAIN CONTAINING MOLECULES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-13 | — | — | US | disclosed |
| WO-2024086767-A2 | GLYCAN CONJUGATE COMPOSITIONS AND METHODS | GANNA BIO, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20240132956-A1 | NUCLEIC ACID SEQUENCING COMPONENTS INCLUDING A GLYCOLIPID BI-LAYER | ILLUMINA, INC. | 2024-04-25 | — | — | US | disclosed |
| WO-2024073506-A1 | NUCLEIC ACID SEQUENCING COMPONENTS INCLUDING A GLYCOLIPID BI-LAYER | ILLUMINA, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2023183781-A2 | LEGIONAMINIC ACID GLYCOSYLTRANSFERASES FOR CHEMOENZYMATIC SYNTHESIS OF GLYCANS AND GLYCOCONJUGATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023092188-A1 | \"COMPOUNDS AND METHODS\ | DemAgtech Pty Ltd (AU) | 2023-06-01 | — | — | WO | disclosed |
| US-20230140486-A1 | FUSION PROTEIN AND METHOD OF DETECTING BACTERIA HAVING PSEUDAMINIC ACID | ACADEMIA SINICA (TW) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189797-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE BINDING DOMAIN CONTAINING MOLECULES | CACYBP, MGAM, MASP2 | L3MBTL1 2639/4885NANP 1105/4885 |
| US-20240190913-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE CONTAINING MOLECULES USING THE SAME | MGAM, MASP2, MGAM2 | L3MBTL1 4034/4885NANP 282/4885 |
| US-20250197905-A1 | LEGIONAMINIC ACID GLYCOSYLTRANSFERASES FOR CHEMOENZYMATIC SYNTHESIS OF GLYCANS AND GLYCOCONJUGATES | FNTA, MAGT1, FNTB | L3MBTL1 2329/4885NANP 204/4885 |
| US-20240190912-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE CONTAINING MOLECULES USING THE SAME | MGAM, CA14, MASP2 | L3MBTL1 3910/4885NANP 357/4885 |
| US-20250242035-A1 | GLYCAN CONJUGATE COMPOSITIONS AND METHODS | SIGLEC7, SIGLEC9, ENGASE | L3MBTL1 3738/4885NANP 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.